Loading clinical trials...
Loading clinical trials...
A Phase 2, Double-Blind, Placebo-controlled, Randomized Study Evaluating the Efficacy, Safety, and Tolerability of Sage-324 in the Treatment of Individuals With Essential Tremor
Conditions
Interventions
SAGE-324
SAGE-324 Placebo
Locations
27
United States
Sage Investigational Site
Phoenix, Arizona, United States
Sage Investigational Site
Rogers, Arkansas, United States
Sage Investigational Site
Fresno, California, United States
Sage Investigational Site
Long Beach, California, United States
Sage Investigational Site
Englewood, Colorado, United States
Sage Investigational Site
Boca Raton, Florida, United States
Start Date
May 19, 2020
Primary Completion Date
February 1, 2021
Completion Date
February 15, 2021
Last Updated
April 17, 2024
NCT07428447
NCT07417280
NCT04212780
NCT03984643
NCT01581580
NCT06899022
Lead Sponsor
Sage Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions